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OncoClinical and Ultrasonic Evaluation of Spleen Size during
Peripheral Blood Progenitor Cell Mobilization
by Filgrastim: Results of an Open-Label Trial
in Normal Donors
Patrick J. Stiff,1 William Bensinger,2 Muneer H. Abidi,3 Roger Gingrich,4 Andrew S. Artz,5
Auayporn Nademanee,6 Keith S. Hansen,7 Christopher Sobczak,8 Corey Cutler,9
Brian Bolwell,10 Tsiporah B. Shore,11 Hillard M. Lazarus,12 Andrew M. Yeager,13
Wade Lovelace,14 Matthew Guo,14 Lyndah Dreiling14Rare reports of splenic rupture have been associated with filgrastim treatment during peripheral blood pro-
genitor cell (PBPC) mobilization in allogeneic donors. We performed a prospective study of spleen volume
change in 309 normal donors who received filgrastim according to local institutional practices. Splenic assess-
ments consisted of ultrasonography and clinical examination at baseline and on the first day of leukapheresis in
304 donors. Of these, 90 donors were also examined 2 and 4 days after the first leukapheresis and 7 days after
the last leukapheresis. Median spleen volume increased 1.47-fold (range: 0.63 to 2.60) on the first leukaphe-
resis day and declined to near pretreatment levels at 7 days after last leukapheresis. Nine percent of donors
had$2-fold increase in splenic volume. Spleen palpability did not correlate with change in spleen volume. No
donors experienced a splenic rupture. Therewas no correlation between change in spleen volume and filgras-
tim dosage, number of doses/day, peak absolute neutrophil count (ANC), CD341 yield, or donor baseline
weight. Most donors experienced $1 adverse event, with 6 donors reporting serious adverse events. We
conclude that the increase in splenic volume during PBPC mobilization in donors was transient, and that fil-
grastim was well tolerated in this study. This trial was registered at www.ClinicalTrials.gov as NCT00115128.
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Mobilized peripheral blood progenitor cells
(PBPC) are frequently used in allogeneic stem cell (SC)
transplantation for hematologic disorders [1]. From
2002 to 2006, approximately 72% of allogeneic SC
transplants performed in adults in the United States
used PBPC, outpacing bone marrow (BN) as the
most frequent source of donor hematopoietic cells [2].1Division of Hematology/Oncology, Loyola University
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of filgrastim use in PBPC mobilization [4]. In a retro-
spective analysis from the International Bone Marrow
Transplant Registry (IBMTR) and the European Blood
andMarrow Transplant Group (EBMT), the incidence
of serious complications was infrequent, occurring in
1% of 1488 donors receiving G-CSF for PBPCmobili-
zation, with a safety profile that was comparable to BM
harvesting. Within this experience, rare case reports of
splenic rupture following G-CSF treatment have been
reported [5-18]. Reported estimates of the incidence of
splenic rupture vary in the literature from 0.08%
[7,19] to approximately 1% [20].
Previous studies have reported changes in splenic
size during PBPC mobilization with G-CSF, but did
not take into account changes in splenic volume. The
changes in size ranged from a 1.1-fold increase in maxi-
mal splenic length and width [21], to an increase in
splenic lengthof 13.8%[22] andanestimatedvolume in-
crease of 122% [23]
The purpose of the current study was to accurately
assess the change in splenic volume in allogeneic
PBPC donors during filgrastim administration. In
contrast to other studies where the splenic length
with or without the width dimension was used to dem-
onstrate size changes, this study estimated splenic vol-
ume by ultrasonic measurement of the spleen in 3
dimensions. The primary endpoint was fold change
from baseline in spleen volume in postbaseline mea-
surements during mobilization as measured by ultra-
sound. The secondary endpoints of splenic palpation,
hematologic values, and filgrastim dosing (ie, dose,
frequency, and schedule) were correlated with spleen
volume. Safety was measured by reports of adverse
events.MATERIALS AND METHODS
Donor Recruitment
Related and unrelated donors were eligible for
PBPC donation according to local institutional crite-
ria, plus the following protocol-specific criteria: age
$18 years, no history of splenectomy, no known pre-
vious treatment with G-CSF or granulocyte macro-
phage colony-stimulating factor (GM-CSF), and no
previous PBPC mobilization.
The study was approved by the institutional review
board of each participating institution. Written in-
formed consent was obtained from all participants.Investigational Product and Administration
This was an open-label, single-arm study. Donors
were administered filgrastim (NEUPOGEN, Amgen
Inc, Thousand Oaks, CA) by subcutaneous injection at
a dosage, frequency, and schedule consistent with localinstitutional practice or National Marrow Donor Pro-
gram guidelines.Assessments
Baseline splenic ultrasound and palpation assess-
ments were performed on day 1, before the first dose
of filgrastim was administered. Splenic assessments
were repeated on the day of the first leukapheresis, 2
days and 4 days after the first leukapheresis, and 7 days
after the last leukapheresis (Figure1).On thedaysof leu-
kapheresis, donors, who were nonfasting, underwent
splenic assessment before apheresis. Ninety donors
completed the study according to this schedule. After
an interim analysis, the protocol was amended to reduce
the number of splenic assessments to facilitate accrual.
Thereafter, the remaining 219 donors were evaluated
only at baseline and the first day of leukapheresis (Fig-
ure 1). Complete blood counts (CBCs) and CD341
cell yield (per kilogram [kg]of donorweight)weredeter-
mined on the same day as ultrasound assessment. Ad-
verse events were followed through 7 days after the last
leukapheresis for all donors.
Splenic measurement was performed by a certified
sonographer. Although a 3.5-MHz broadband curvi-
linear probe was the minimum recommended, the
highest frequency transducer that allowed visualiza-
tion was used. If able to visualize, the subject was exam-
ined while supine; otherwise. a right lateral decubitus
approach was used in a longitudinal (coronal) axis of
the spleen. A posterolateral approach was recommen-
ded, with the probe footprint aligned along an inter-
costal space. Measurements were made without
inspiration unless the spleen was masked by the lung
and then a deep inspiration was used to minimize
and eliminate morphologic masking and variation dur-
ing respiration.
Splenicmeasurements (transverse, longitudinal, and
diagonal; Figure 2) were made on ultrasonographic im-
ages. The longitudinal diameter was defined as the
greatest dimension of the spleen in a longitudinal image
through the hilum; the transverse diameter was defined
as the greatest dimension in a transverse image through
the hilum; and the diagonal diameter (thickness) was de-
termined in the transverse image through the hilum as
the distance from the hilum to the outer convex surface,
approximately perpendicular to the transverse diameter
[24]. The splenic volume was estimated by multiplying
the product of the longitudinal, transverse, and diagonal
diameters (measured in centimeters [cm]) by a factor of
0.523, to approximate the volumeof an ellipse [24]. Fold
changewas calculated as the ratio of volume atmeasure-
ment to baseline volume.
Physical palpation and ultrasonography of the
spleen were performed on the same day in no prespeci-
fied order. Clinicians performing splenic palpation
were blinded to that day’s ultrasonographic results,
Study
Day
Study
Day
1
Original
Protocol
n = 90
Amended
Protocol
n = 219
= Splenic ultrasound and physical palpation
Last
LP+7
Days
LP+4
Days
LP+2
DaysLP
1 LP
LP = Leukapheresis
Figure 1. Schedule of splenic evaluations by ultrasound and physical palpation. Adverse events were followed through 7 days after the last leukapheresis
for both versions of the protocol. aDonors treated under the amended protocol continued leukapheresis without ultrasound or physical palpation
examinations.
Biol Blood Marrow Transplant 15:827-834, 2009 829Splenic Evaluation after Filgrastim Treatmentand sonographers were blinded to that day’s palpation
result to reduce bias. If necessary for medical care, the
clinician was permitted to review that day’s ultrasono-
graphic results after the physical exam and palpation
were completed and results recorded.Statistical Analysis
Statistical analyses were descriptive in nature. Con-
tinuous variables were summarized by mean, standard
deviation,median, first and third quartiles, and extreme
values. Categoric variables were summarized with re-
spect to frequency and percentage of each category.
The primary endpoint was the fold change from
baseline in spleen volume in postbaseline measure-
ments during mobilization as measured by ultrasonog-
raphy. The Spearman Rank correlation coefficient was
used to examine the relationship between fold change
in spleen volume and secondary endpoints, including
spleen palpability, hematologic values, filgrastim dos-
age, frequency, and schedule. Linear regression analy-
sis was used to investigate the relationship between
fold change in spleen size and age. The number andT
d
th
D
m
th
th
p
Longitudinal diameter (L) is the greatest
dimension of the spleen on a longitudinal
image through the hilum
L
Figure 2. Spleen evaluations assessedpercentage of donors with adverse events were also
summarized.
The clinical hypothesis was that the spleen may in-
crease dimensionally and volumetrically with filgrastim
administration and PBPC mobilization without serious
or significant clinical sequelae. The sample size of ap-
proximately 300 donors provided 95% probability of
observing at least 1 occurrence of an adverse event
that would be expected to occur in 1.25% or more of
donors receiving filgrastim. Incidence rates in this study
were estimated with a standard deviation of\3%.RESULTS
Subject Characteristics
Three-hundred nine allogeneic PBPC donors (re-
lated or unrelated) were enrolled and received at least 1
filgrastim dose at 14 clinical sites between November
2003 and May 2007. Donors were men and women
ranging from 18 to 74 years of age, and were from sev-
eral racial backgrounds (Table 1). Themedian baselineransverse diameter (T) is the greatest
imension on a transverse image through
e hilum
iagonal diameter (D; thickness)
easured in transverse image through
e hilum as the distance from the hilum to
e outer convex surface, approximately
erpendicular to the transverse diameter
T
D
by ultrasound in 3 dimensions.
Spleen Fold Change
Leukapheresis 1
Median 1.47 (n = 304)
Leukapheresis 1 + 2 days
Median 1.41 (n = 88)
Leukapheresis 1 + 4 days
Median 1.19 (n = 86)
Last Leukapheresis + 7 days
Median 1.08 (n = 89)
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Figure 3. Distributions of spleen volume fold change on leukapheresis
day 1, leukapheresis day 11 2 days, leukapheresis day 11 4 days, and the
last day of leukapheresis1 7 days. Solid line indicates a fold change5 1.
Dashed line indicates median.
830 Biol Blood Marrow Transplant 15:827-834, 2009P. J. Stiff et al.spleen volume was 249.9 cm3 (range: 42-1077). The
minimum spleen volume was observed in a 44-year-
old female donor weighing 65.5 kg and the largest
spleen volume was observed in a 23-year-old male do-
nor weighing 155 kg. A total of 306 donors underwent
leukapheresis, and CD341 data were available for 305
donors. Ninety-eight percent (303/309) of the donors
completed the study, and 97% completed filgrastim
treatment.
Filgrastim Dosage and Administration
Themedian daily filgrastim dosage was 10.2 mg/kg,
with a range of 5.0 mg/kg to 31.9 mg/kg. Sixty percent of
donors received an average daily dosage of filgrastim
between 9 mg/kg and 11 mg/kg, with 6% of donors
receiving a dose of 9 mg/kg or less and 10% receiving
a dose over 16 mg/kg. Twenty-six percent of donors
received at least 1 split (morning and evening) filgras-
tim dose; the remainder received all once-daily doses.
The median duration of filgrastim dosing was 5 days
(range: 1-8 days).
Spleen Assessment
The primary endpoint, median fold change in
spleen volume from baseline, was 1.47-fold (range:
0.63-2.60) from baseline to the first day of leukaphere-
sis, followed by a progressive decrease, returning to
1.08-fold (range: 0.68-2.83) from baseline level by 7
days after the last leukapheresis (Figure 3). Twenty-
six of 305 (9%) donors evaluated had a $2-fold in-
crease in spleen volume.Median fold changes in spleen
volume were similar for donors receiving filgrastim
doses above or below 10 mg/kg/day and for donors re-
ceiving once daily filgrastim or twice daily filgrastim
(at least 1 split dose). Median fold change in spleen vol-
ume was similar for men and women and was compa-
rable across all races enrolled in the study. No
donors with $2-fold change in spleen volume
experienced serious adverse events, withdrew fromTable 1. Donor Demographics and Baseline Characteristics
Characteristic Value
Subjects, N 309
Median age, years (range) 44.0 (18, 74)
Sex, male/female, N 173/136
Race, N (%)
African American or black 20 (6)
Caucasian or white 265 (86)
Other 24 (8)
Median baseline weight, kg (range) 85.1 (42, 217)
Median baseline height, cm (range) 171.5 (87, 198)
Median baseline spleen volume, cm3 (range)* 249.9 (42, 1077)
Spleen palpability at baseline, N (%)
Nonpalpable 304 (98)
Palpable 2 (1)
Missing data 3 (1)
*Spleen volume 5 (longitudinal length  transverse length  diagonal
length)  0.523.the study prematurely, or discontinued filgrastim
early. The only characteristic that was identified that
predicted a$2-fold change in spleen volume was older
age, ranging from a median change (minimum, maxi-
mum) at the first leukapheresis of 1.35 (0.63, 2.41) in
donors from 18 to 29 years to 1.52 (0.73, 2.41) in do-
nors 60 years of age or older. The linear regression
analysis indicated age was a significant predictor for
fold change in spleen size from baseline at the first
leukapheresis (P 5 .0449).
The maximum fold change in any donor was 2.9,
which occurred on the second day of leukapheresis
(study day 6) in a 63-year-old white woman with a his-
tory of multiple medical problems. She had received
filgrastim 6.99 mg/kg/day in a split dose for 5 days.
The spleen was palpable in 19 of 861 exams (2.2%),
including 2 baseline assessments, representing 14 do-
nors. There was no relationship between splenic pal-
pability and increase in spleen volume. Although 26
donors (9%) had a $2-fold increase in spleen volume,
only 1 of these donors had a palpable spleen postbase-
line. This donor had a 2.9-fold change in spleen vol-
ume, and the spleen was palpable at exams on days 9
and 10. Twelve of 17 palpable spleens after baseline
had corresponding fold changes between 1.0 and 1.5,
which was at or below the median fold change (1.47)
for the population. Tenderness or guarding on physi-
cal examination was reported by 8 donors, 2 of whom
also exhibited a palpable spleen.
Relationship between Volume Change and
Other Characteristics
Hematologic and leukapheresis results are pre-
sented in Table 2. Peak absolute neutrophil count
(ANC) duringmobilizationwas not significantly corre-
lated with splenic volume fold change (Spearman Rank
coefficient 5 0.06-0.17 [minimum to maximum ob-
served across leukapheresis time points, respectively]).
Neither CD341 cell yield (per kg donor weight) nor
Table 2. Characteristics of Leukapheresis Administration
and Blood Analysis
Characteristic/parameter Value
Days to first leukapheresis 5 (3, 7)
N 5 305
Median (minimum, maximum)
Number of leukaphereses 2.0 (1, 4)
N 5 309
Median (minimum, maximum)
Total CD34+ yield (106 cells/kg) 7.8 (5.4, 11.6)
N 5 309
Median (Q1, Q3)
Blood processed (L) per leukapheresis 14.0 (12, 20)
N 5 467
Median (Q1, Q3)
Maximum ANC (109/L) 34.7 (27.5, 42.6)
N 5 467
Median (Q1, Q3)
Note: Donors who withdrew before commencing leukapheresis were
excluded from the summary of leukapheresis administration; therefore,
CD34+ data were available for 305 of the 309 donors that received
filgrastim.
ANC indicates absolute neutrophil count; Q1, 25th percentile; Q3, 75th
percentile.
Biol Blood Marrow Transplant 15:827-834, 2009 831Splenic Evaluation after Filgrastim Treatmentbaseline body weight was significantly correlated with
splenic volume change (Spearman Rank coefficient 5
20.06-0.05 and 20.12-0.06, respectively). Although
there was a wide range of filgrastim dosages adminis-
tered, and daily frequency (once per day or in split or
2 doses per day), these variables were not significantly
correlated with fold change in spleen volume (Spear-
man Rank coefficient 5 20.07-0.06 and 20.10-0.05,
respectively).
Adverse Events
Of the 309 donors enrolled, 292 (94%) had at least
1 adverse event. The most common adverse events
were headache (44%) and bone pain (36%), both of
which were generally considered related to filgrastim
(42% and 36%, respectively). Most adverse events
were considered to be mild or moderate in intensity
and no donors experienced adverse events that were
considered life-threatening or fatal. Severe adverse
events experienced by more than 1 donor are listed
in Table 3. Six donors (2%) experienced serious ad-
verse events, which led to study withdrawal for 3 do-
nors (Table 3). None of the donors with $2-fold
change in spleen volume experienced serious adverse
events, withdrew from the study prematurely, or dis-
continued filgrastim early. Upper abdominal pain (all
mild to moderate severity) was reported by 6 donors.DISCUSSION
This is the largest study designed to assess changes
in spleen size during PBPCmobilization with filgrastim
in normal donors who were scheduled for PBPCmobi-
lization and collection. The change in spleen volume
was accurately measured by 3-dimensional ultrasono-graphic analysis following filgrastim administration in
‘‘normal’’ donors of PBPC. To be able to review spleen
size dynamics across the range of real-world practices,
filgrastim was administered according to institutional
standard practices, National Marrow Donor Program
(NMDP), or other similar guidelines.
The results of this study suggest that increases in
spleen volume following filgrastim administration
were transient, peaked on the first day of leukapheresis
(median fold change 1.47), and returned to near baseline
levels by 7 days after the last leukapheresis (median fold
change 1.08). Changes in spleen volume did not corre-
late with filgrastim dose level or frequency, or with total
CD341 yield, ANC, or baseline weight. Median fold
change from baseline tended to be largest for the oldest
donors ($60 years); this is hypothesized to be related to
the spleen’s increased role in myelopoiesis or increased
intrasplenic accumulation of circulating granulocytes
and myeloid precursors in the spleens of older donors
undergoing mobilization. Preclinical models have sug-
gested decreasing hematopoietic stem cell homing after
mobilization with aging [25,26], which could result in
splenic accumulation of progenitor and stem cells.
No donors experienced splenic rupture in this
study. However, the incidence of splenic rupture may
be too rare to be detected in a study of 309 individuals.
This study was powered to detect an event that oc-
curred with a frequency of 1.25% or more, but the
risk is probably much lower. Between February 1997
and November 2007, 7669 donors underwent filgras-
tim-stimulated PBPC collection coordinated by the
NMDP. No donors had splenic bleeding or rupture
or other abdominal catastrophe during mobilization
(D. Confer, personal communication, 2007). World-
wide, only 6PBPCdonorswere identified as experienc-
ing splenic rupture after G-CSF mobilization in
a comprehensive literature review (Table 4). There-
fore, splenic rupture is uncommon in PBPC donors
mobilized by G-CSF. The question of why the spleen
enlargesmay be best answered from the cases of splenic
rupture identified (D.C. Dale, personal communica-
tion, 2008). Four of the 6 donors with splenic rupture
required a splenectomy. The histology of each of the
removed spleens indicated extramedullary myelopoie-
sis possibly leading to expansion of the hematopoietic
tissue in the spleen with the new blood cell formation
(D.C. Dale, personal communication, 2008). This hy-
pothesis has also been considered by others [23].
Approximately 10% of donors had $2-fold in-
creases in spleen volume.These increases did not corre-
spond with spleen palpability on physical examination.
The most frequently reported adverse event among do-
nors with $2-fold increase in spleen volume was back
pain, which occurred in 38%of donors in this subgroup
compared with 25% of the overall study population.
The utility of palpating for the spleen on physical
examination was not evident. Spleen palpability did
Table 3. Summary of Adverse Events
N (%), n 5 309
Bone pain (includes: bone pain, arthralgia, musculoskeletal pain, and back pain if related to filgrastim) 5 (2%)
Vomiting 3 (1%)
Headache 3 (1%)
Dyspnea 2 (1%)
Nausea 2 (1%)
Pain 2 (1%)
Serious adverse events
Demographics Primary event Related*/withdrawn† Filgrastim (mg/kg/day) Max fold change Palpability Max ANC (109/L)
Male, 37 years, 94.6kg Chest discomfort/dyspnea Yes/Yes 10.15 (split‡) ND§ ND§ ND§
Male, 27 years, 169.0kg Tachycardia/chest pain/dyspnea Yes/Yes 16.0 (split) 1.5 No 30.26
Male, 41 years, 88.1kg Back Pain Yes/Yes 10.9 ND§ ND§ 29.67
Female, 27 years, 50.0kg Nausea/Vomiting Yes/No 12.0 1.7 No 72.35
Male, 45 years, 80.1kg Pericarditis No/No 11.24 1.4 No 39.83
Female, 38 years, 70.8kg Catheter complications No/No 20.35 (split) 1.5 No 59.18
Severe adverse events occurring in $1 of donors.
ANC indicates absolute neutrophil count; kg, kilogram; max, maximum.
*Event considered related to filgrastim by investigator.
†Donor withdrawn from study.
‡Filgrastim dose was split and given in the morning and the evening.
§ND, No postbaseline assessments done.
832 Biol Blood Marrow Transplant 15:827-834, 2009P. J. Stiff et al.not correlate with increased spleen volume. Splenic
examinations where the spleen was considered palpa-
ble were often not the assessment at which the spleen
was at its largest volume. Similarly, guarding, pain, or
tenderness on examination did not correspond with
maximum increases in spleen volume. In some cases,
these events may have resulted from the process of
the examination itself (ie, pressure applied during ex-
amination) and not by splenic changes. Consistent
with previous reports, physical examination may be
ineffective in diagnosing splenomegaly, in part be-
cause of differences in donor body size and habitus
[27].
The frequency of adverse events observed in this
study was similar to those observed in other studies
of filgrastim, and were consistent with previously re-
ported data [28]. Reported adverse events were largely
events previously associated with either filgrastim use
or the leukapheresis procedures.
In summary, increase in spleen size during PBPC
mobilization with filgrastim was common, but tran-
sient. Spleen palpability was rare, and did not corre-
late with increase in splenic volume. Spleen volume
fold change was not correlated with filgrastim dosage
or schedule, ANC values, CD341 yield, or donor
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